An Open-label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin Administered in Combination With Rituximab Compared to Defined Investigator's Choice Therapy in Subjects With Relapsed or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma Who are Not Candidates for Intensive High-Dose Chemotherapy

Trial Profile

An Open-label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin Administered in Combination With Rituximab Compared to Defined Investigator's Choice Therapy in Subjects With Relapsed or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma Who are Not Candidates for Intensive High-Dose Chemotherapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Inotuzumab ozogamicin (Primary) ; Bendamustine; Gemcitabine; Rituximab
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms INO-VATE
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Aug 2017 Brazil, Greece, Hong Kong, Netherlands, Poland, Portugal, Puerto Rico, Slovakia, Switzerland and Turkey were planned locations of this trial, as reported in the European Clinical Trials Database record
    • 25 Jun 2017 Results evaluating region-specific hospitalization days per patient from safety population of this trial (n=264) presented at the 22nd Congress of the European Haematology Association
    • 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top